The Analyst Verdict: bluebird bio In The Eyes Of 5 Experts
Portfolio Pulse from Benzinga Insights
Analysts have mixed views on bluebird bio (NASDAQ:BLUE) with recent ratings showing a mix of bullish and bearish perspectives. The average 12-month price target has declined by 26.92% to $3.8. Analysts have adjusted their ratings and price targets, reflecting dynamic market conditions and company performance. Despite a positive revenue growth rate of 680.05%, bluebird bio faces challenges with a high debt-to-equity ratio and negative ROE and ROA.
September 25, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
bluebird bio (NASDAQ:BLUE) has received mixed analyst ratings, with a decline in the average 12-month price target by 26.92% to $3.8. Despite a significant revenue growth rate of 680.05%, the company faces challenges with a high debt-to-equity ratio and negative ROE and ROA.
The mixed analyst ratings and significant drop in the average price target suggest uncertainty in the short-term outlook for bluebird bio. While the company shows strong revenue growth, financial challenges such as high debt and negative ROE/ROA may offset positive sentiment, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100